Johnson & Johnson has announced positive results from pre-clinical trial for its lead vaccine candidate that protects against SARS-CoV-2, the virus that causes COVID-19. According to recently published data, the company’s adenovirus serotype 26 (Ad26) vector-based...
Pfizer Inc. (NYSE:PFE) reached an agreement with the US government to supply 100 million doses of a vaccine the company is developing in partnership with BioNTech SE – ADR. In the agreement, the US government has paid $2 billion to the company to have it deliver the...
